Results Evidence suggests that GLP-1RAs mitigate psoriasis severity through systemic effects, including weight loss and improved glycemic control, and local immunomodulation, such as the regulation of invariant natural killer T (iNKT) cells and AMPK activation in psoriatic plaques
The magnitude of this cortisol response is dose- and route-dependent
These findings may be explained by lower doses administered SC not adequately neutralizing IL-5 within the airways, despite attenuated peripheral eosinophilia
#Semaglutide #terzepatide #GLP-1 #Obesity management To view or add a comment, sign in One of the latest weight loss drugs, tirzepatide, has shown even better results than ozempic in people with obesity and type 2 diabetes
Advanced Testing and Monitoring For my patients with known or suspected hemochromatosis, I recommend comprehensive testing that goes beyond basic iron studies, including the approach I detail in my article on assessing your total toxic burden: Oxidative Stress Markers: Lipid peroxidation markers (malondialdehyde, F2-isoprostanes) Antioxidant enzyme levels (superoxide dismutase, catalase, glutathione peroxidase) Total antioxidant capacity Genetic Testing: Complete HFE genotyping (C282Y, H63D, S65C variants) Antioxidant enzyme genetic variants Detoxification pathway genetic analysis Comprehensive Toxin Assessment: Given the connection between iron overload and increased susceptibility to other environmental toxins, I often recommend testing for mycotoxins, heavy metals, and environmental chemicals as discussed in my toxic load assessment protocols
This installment also features two FDA warning letters directed at GLP-1 compounding pharmacies because of violations at their manufacturing facilities
.png.jpg)
